Comparative Pharmacology
Head-to-head clinical analysis: OSMITROL 10 IN WATER IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
Head-to-head clinical analysis: OSMITROL 10 IN WATER IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.
Initial: 0.25–1 g/kg (25–100 mL of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.
Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 mL of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.
None Documented
None Documented
Terminal half-life approximately 1.5 hours in normal renal function; prolonged in renal impairment (up to 36 hours in anuria).
The terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal renal function. This can be prolonged to 6-12 hours in patients with renal impairment, requiring dose adjustment.
Primarily renal; >90% excreted unchanged in urine via glomerular filtration; <5% biliary/fecal.
Mannitol is excreted primarily by the kidneys via glomerular filtration, with approximately 80% of an administered dose appearing unchanged in urine within 3 hours. Less than 10% undergoes tubular reabsorption; negligible biliary or fecal elimination (<1%).
Category C
Category C
Osmotic Diuretic
Osmotic Diuretic